The Cancer Advisor

Keytruda - $29.5 billion Darzalex - $9 billion Opdivo - $7 billion Imbruvica - $5billion Tagrisso - $5 billion Revlimid - $4 billion Verzenio - $4 billion Imfinzi - $4 billion Ibrance - $3 billion Tecentriq - $3 billion In the rapidly evolving field of oncology, several cancer drugs have become best-sellers due to their proven effectiveness against various cancer types. Below, we examine some of the top-selling cancer drugs, highlighting their FDA-approved indications, mechanisms of action, and sales figures. 1. Keytruda (Pembrolizumab) - $29.5 billion Indications Approved by FDA: Non-small cell lung cancer (NSCLC) Melanoma Head and neck squamous cell carcinoma (HNSCC) Classical Hodgkin lymphoma Urothelial carcinoma Gastric cancer Esophageal cancer Triple-negative breast cancer (TNBC) Renal cell carcinoma (RCC) Microsatellite instability-high (MSI-H) cancers Colorectal cancer Hepatocellular carcinoma (HCC) Cervical cancer Mechanism of Action: Keytruda is a monoclonal antibody that targ...

Facing a cancer diagnosis can feel like navigating an endless maze with no clear direction. The overwhelming emotions and confusion that accompany such news are shared by many. While conventional cancer treatments like chemotherapy and radiation therapy have a role to play, there’s a growing interest in alternative therapies that can complement or even replace traditional methods. Did you know that many alternative cancer treatments have been explored, offering new hope to those affected by cancer? The use of complementary and alternative medicine is becoming more prevalent as patients seek options beyond conventional medical treatments. Alternative medicine includes therapies used outside of standard medical practices, offering different approaches to treat cancer. Integrative medicine combines both conventional and alternative treatments, aiming to improve outcomes and enhance quality of life. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created...